AE-941 in Treating Patients With Metastatic Kidney Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: AE-941 may stop the growth of kidney cancer by stopping blood flow to the tumor.
PURPOSE: Randomized phase III trial to determine the effectiveness of AE-941 in treating
patients who have metastatic kidney cancer that has not responded to biological therapy.